ARA-290 (Cibinetide): What the Research Shows

Research Use Only: This article summarises published scientific literature for laboratory and research audiences. It is not medical advice, and ARA-290 is not approved for human or veterinary use in this context.

What is ARA-290?

ARA-290 (Cibinetide) is a synthetic peptide derived from a region of the erythropoietin (EPO) molecule. Unlike EPO, it is studied for signalling through the innate repair receptor rather than the classic erythropoietic pathway, and it is a common subject in tissue-protection and neuroimmune research.

Where ARA-290 sits in the research literature

The evidence base includes preclinical and some clinical research on the innate repair receptor and neuropathic pathways. Findings should be interpreted within their study context.

Reported areas of preclinical interest

• Innate repair receptor: studied for tissue-protective signalling distinct from erythropoiesis.
• Neuroimmune pathways: examined in neuropathic and inflammation research models, including TRPV1-related nociception.

Why the “research use only” label matters

ARA-290 is supplied as a research material and is intended strictly for laboratory and scientific research, not for human or veterinary consumption.

Handling and storage

Store lyophilised peptide cool, dry and away from light, and refrigerate reconstituted solution, using it within the indicated stability window. Follow the documentation supplied with each batch.

Frequently asked questions

What is ARA-290 studied for?

It is studied for innate-repair-receptor signalling and neuroimmune pathways in laboratory models.

Is ARA-290 approved for human use?

The material supplied here is a research chemical only and is not intended for human or veterinary use.

Key takeaways

ARA-290 (Cibinetide) is an EPO-derived peptide studied for innate-repair-receptor and neuroimmune pathways. It is a research material only. Review the ARA-290 research product.

References

References sourced via PubMed.

1. Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: integration between immune system and nociception. Peptides. 2016;76:73-79. DOI · PubMed 26774587.

Disclaimer: This article is for informational and educational purposes for a research audience. It is not medical advice. Products referenced are sold strictly for laboratory research and are not for human or veterinary use.